Canada In Vitro Diagnostics Market Trends
Projected to have a CAGR of 4.8%, the USD 8.05 billion Canada in vitro diagnostics market size in 2024 is One of the main drivers projected to propel development is the rising frequency of chronic diseases like cancer, inflammatory problems, autoimmune diseases, and infectious diseases. Additionally, increases in the geriatric population and advancements in in vitro diagnostics (IVD) devices are expected to drive market growth.
The prevalence of various diseases, such as cancer, autoimmune diseases, and inflammatory conditions, is increasing in Canada, which is expected to drive the demand for IVD testing. For instance, according to the Canadian Cancer Society, approximately 239,100 Canadians were expected to be diagnosed with cancer in 2023, and about 86,700 deaths were anticipated to be reported from cancer.
Moreover, according to the Canadian Congenital Heart Alliance, about 1 in 80 to 100 children in Canada is born with congenital heart disease (CHD). An estimated 257,000 Canadians suffer from CHD. The increasing prevalence of chronic diseases and growing awareness about early disease diagnosis are expected to further drive the demand for in vitro diagnostic services in the country.
Canada’s geriatric population is gradually increasing. The number of people aged 65 and older is expected to grow by 68%, reaching 10.4 million by 2037. This growth is reported across all provinces and territories in Canada. As people age, their immune systems weaken, increasing their susceptibility to various diseases. Hence, a growing geriatric population requires improved healthcare services, particularly for chronic conditions.
As the population ages, the need for frequent and accurate diagnostic tests to manage age-related health conditions increases. Technological advancements have improved the precision, efficiency, and accessibility of these tests, enabling better health monitoring and early disease detection.
Product Insights
The reagents segment dominated the market with the largest revenue share of 65.5% in 2024, owing to totheir crucial role in diagnostic tests. Reagents are essential for disease detection, resulting in high demand across laboratories and diagnostic centers. This widespread usage has led to significant revenue growth, solidifying the segment’s prominence. The increase in the reagent segment is due to things like more research and development efforts by companies to create new biomarker kits and the growing sale of reagents, which is likely to boost the need for them in the coming years.
The instruments segment is projected to grow at a significant CAGR of 4.5% from 2025 to 2030. Technological advancements in products and the high demand for advanced in vitro diagnostic devices bolster this growth. For instance, the introduction of portable instruments such as Cobas 4800, developed by Roche Diagnostics, and GeneXpert by Cepheid may fuel the Canadian IVD market's growth over the forecast period.
Report Coverage & Deliverables
The PDF report & online dashboard will help you understand
- Competitive benchmarking
- Historical data & forecasts
- Company revenue shares
- Regional opportunities
- Latest trends & dynamics
Technique Insights
The molecular diagnostics segment held the largest market share in 2024, attributed to its crucial role in accurately diagnosing a wide range of diseases. This growth is fueled by advancements in technologies like PCR and next-generation sequencing, along with the rising prevalence of infectious diseases, genetic disorders, and cancer. Increased product approvals, launches, and R&D by key players have further strengthened the segment.
The coagulation segment is expected to be the fastest-growing segment over the forecast period. We expect the increasing prevalence of cardiovascular diseases, blood-related disorders, and autoimmune diseases to boost the demand for coagulation testing using IVD instruments. Moreover, instruments are getting updated, and handheld coagulation analyzers, such as the Xprecia Stride model, are anticipated to enhance the overall workflow of detection.
Application Insights
The infectious disease segment accounted for the largest market share in 2024, attributed to the high prevalence of infectious diseases and the need for accurate and timely diagnostics. The demand for rapid testing and early detection has increased, particularly during public health emergencies. Continuous advancements in diagnostic technologies have further propelled the growth of this segment. The widespread application of infectious disease diagnostics in hospitals, clinics, and laboratories has cemented its dominance.
The oncology segment is anticipated to be the fastest-growing segment over the forecast period, driven by the rising incidence of cancer and the demand for early and accurate diagnostics. Technological innovations, particularly liquid biopsies and molecular testing, are improving cancer detection and monitoring. In addition, awareness campaigns and government initiatives promoting cancer screening are boosting this growth.
End Use Insights
The hospital segment held the largest share in 2024, owing to its pivotal role in patient care and diagnostics. Hospitals are major healthcare providers, conducting a wide range of diagnostic tests for various conditions. The high volume of patients, coupled with the availability of advanced diagnostic technologies, contributes to the dominance of this segment. In January 2022, Yourgene announced the launch of expanded facilities under Yourgene Health Canada Inc. The new facilities are expected to be well suited for the company’s consumable shipping requirements and instrument manufacturing.
The home care segment is projected to be the fastest-growing segment over the forecast period, propelled by the shift towards personalized healthcare and convenience. With the rise of chronic diseases and an aging population, more individuals are seeking at-home diagnostic solutions for early detection and ongoing monitoring.
Test Location Insights
The "others" test location segment, including outpatient clinics and private laboratories, garnered the largest share in 2024 due to the broad range of diagnostic settings these locations offer, providing diverse and convenient testing options for patients. The shift toward specialized testing services outside of traditional hospital environments has substantially contributed to the growth of this segment. Moreover, advancements in technology and a focus on patient-centric care have strengthened the expansion of this segment, securing its dominant position in the Canadian in vitro diagnostics industry.
The home care segment is anticipated to be the fastest-growing segment over the forecast period. Government initiatives and increasing adoption of self-tests are some of the key factors anticipated to boost the segment’s growth over the forecast period. Regulatory authorities rigorously evaluate the performance of diagnostic tests to meet global standards of safety, performance, and quality.
Province Insights
Ontario's in vitro diagnostics market captured the largest revenue share of 31.1% in 2024, fueled by the advanced healthcare infrastructure of the province and the high prevalence of chronic diseases such as cancer and diabetes. Numerous specialized laboratories and diagnostic centers in Ontario have also contributed to this growth. Furthermore, the aging population in the province has increased the demand for diagnostic services, further positioning Ontario as the leading region in the market.
East Canada is anticipated to be the fastest-growing region with a CAGR of 6.1% over the forecast period. The expanding healthcare infrastructure of the region and increasing focus on personalized medicine are significant factors in this upward trajectory. In addition, the rising prevalence of chronic diseases and the aging population are fueling the demand for advanced diagnostic solutions. Technological innovations and the emphasis on early disease detection further contribute to the region's growth. Given these favorable conditions, East Canada has the potential to emerge as a prominent and thriving region in the Canada in vitro diagnostics industry.
Key Canada In Vitro Diagnostics Company Insights
Some of the key companies in the Canada in vitro diagnostics industry include Abbott; bioMérieux SA; Bio-Rad Laboratories, Inc.; Siemens Healthcare GmbH; QIAGEN; Quidel Corporation; F. Hoffmann-La Roche Ltd.; BD; Danaher; and Agilent Technologies, Inc.
-
Abbott offers a diverse range of healthcare solutions, including medical devices, diagnostics, nutrition, and pharmaceuticals. It focuses on improving patient care and health outcomes through innovations in areas such as diabetes management and cardiovascular health.
-
bioMérieux SA offers in vitro diagnostic solutions for clinical laboratories, hospitals, and industries. Its products include systems, reagents, and software for diagnosing infectious diseases, cancer, and cardiovascular conditions, as well as microorganism identification.
Key Canada In Vitro Diagnostics Companies
- Abbott
- bioMérieux SA
- Bio-Rad Laboratories, Inc.
- Siemens Healthineers AG
- QIAGEN
- QuidelOrtho Corporation
- F. Hoffmann-La Roche Ltd
- BD
- Danaher
- Agilent Technologies, Inc.
Recent Developments
-
In March 2024, QuidelOrtho Corporation received approval from Health Canada for its Triage PLGF test for laboratory use. This fluorescence immunoassay, used with the compact Triage MeterPro Instrument, quantitatively measures placental growth factor (PLGF ) in maternal plasma specimens.
-
In August 2023, bioMérieux Canada received Health Canada approval for its BIOFIRE Joint Infection (JI) Panel. This panel can quickly test for 31 pathogens linked to joint infections and 8 antimicrobial resistance (AMR) genes, enhancing timely antibiotic therapy and stewardship.
Canada In Vitro Diagnostics Market Report Scope
|
Report Attribute |
Details |
|
Market size value in 2025 |
USD 8.44 billion |
|
Revenue forecast in 2030 |
USD 10.68 billion |
|
Growth Rate |
CAGR of 4.8% from 2025 to 2030 |
|
Base year for estimation |
2024 |
|
Historical data |
2018-2024 |
|
Forecast period |
2025-2030 |
|
Quantitative units |
Revenue in USD million and CAGR from 2025 to 2030 |
|
Report coverage |
Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
|
Segments covered |
Product, technique, application, end use, test location, province |
|
Province scope |
Ontario; Quebec; West Canada; East Canada |
|
Key companies profiled |
Abbott; bioMérieux SA; Bio-Rad Laboratories, Inc.; Siemens Healthcare GmbH; QIAGEN; Quidel Corporation; F. Hoffmann-La Roche Ltd; BD; Danaher; Agilent Technologies, Inc. |
|
Customization scope |
We offer free report customization, equivalent to up to 8 analysts' working days, with every purchase. Changes or additions to the scope of the country, region, and segment are possible. |
|
Pricing and purchase options |
Avail yourself of customized purchase options to meet your exact research needs. Explore purchase options |
Canada In Vitro Diagnostics Market Report Segmentation
This report forecasts revenue growth at the country level and provides an analysis of the latest industry trends in each of the subsegments from 2018 to 2030. For the purpose of this study, MIR has segmented the Canada in vitro diagnostics market report on the basis of product, technique, application, end use, test location, and province
-
Product Outlook (Revenue, USD Million, 2018-2030)
-
Instruments
-
Reagents
-
Services
-
-
Technique Outlook (Revenue, USD Million, 2018-2030)
-
Immunoassay
-
Instruments
-
Reagents
-
Services
-
-
Hematology
-
Instruments
-
Reagents
-
Services
-
-
Clinical Chemistry
-
Instruments
-
Reagents
-
Services
-
-
Molecular Diagnostics
-
Instruments
-
Reagents
-
Services
-
-
Coagulation
-
Instruments
-
Reagents
-
Services
-
-
Microbiology
-
Instruments
-
Reagents
-
Services
-
-
Others
-
Instruments
-
Reagents
-
Services
-
-
-
Application Outlook (Revenue, USD Million, 2018 - 2030)
-
Infectious Diseases
-
Diabetes
-
Oncology
-
Cardiology
-
Nephrology
-
Autoimmune Diseases
-
Drug Testing
-
Other Applications
-
-
End Use Outlook (Revenue, USD Million, 2018 - 2030)
-
Hospitals
-
Primary Care
-
Laboratories
-
Home Care
-
Others
-
-
Test Location Outlook (Revenue, USD Million, 2018 - 2030)
-
Point of Care
-
Home Care
-
Others
-
-
Province Outlook (Revenue, USD Million, 2018-2030)
-
Ontario
-
Quebec
-
West Canada
-
Alberta
-
Saskatchewan
-
Manitoba
-
British Columbia
-
-
East Canada
-
Nova Scotia
-
Prince Edward Island
-
New Brunswick
-
Newfoundland and Labrador
-
-
Related Reports
FAQ'S
For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:
Within 24 to 48 hrs.
You can contact Sales team (sales@marketinsightsresearch.com) and they will direct you on email
You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.
Discounts are available.
Hard Copy